Skip To Main Content
Lilly
Menu closed
Lilly
    Lilly

    You are now leaving the LillyMedical website

    The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
    Click "Continue" to proceed or "Return" to return to LillyMedical.

    Immunology Journal Publications

    This page includes links to Lilly sponsored trials and observational research that have been published in peer reviewed journals within the last 5 years. Each section is sorted by product and may be expanded for more information. The list of publications below is limited to products that have been approved for use and may contain information about doses, delivery devices, uses, formulations and populations different from product labeling. Clinical decisions should be based on the full safety and efficacy information contained in the product's Full Prescribing Information in the provided link below.

    If you have questions about a Lilly study not listed below or would like to request an electronic copy of one of the journal publications on this page, please call 1-800-LILLYRX (1-800-545-5979). For our publication linking statement click here.

    For all other requests, please visit our Contact Lilly services.

    Olumiant® (baricitinib)

    Full Prescribing Information

    No Publication Journals

    Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials
    Published Date: April 7, 2021
    Video Abstract Link

    Two Phase 3 Trials of Baricitinib for Alopecia Areata
    Published Date: March 26, 2022
    Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials
    Published Date: April 7, 2021
    Video Abstract Link

    No Publication Journals

    Comparing the Burden of Illness in Patients
    Published Date: March 29, 2023
    Cohort profile: patient characteristics and disease burden of alopecia areata in the Danish Skin Cohort (DSC)
    Published Date: February 16, 2022
    The Relationship Between Patient-Reported Severity of Hair Loss and Health-Related Quality of Life and Treatment Patterns Among Patients with Alopecia Areata.
    Published Date: March 29, 2022
    Frequency of prescription claims for drugs that may interact with Janus kinase inhibitors among patients with rheumatoid arthritis in the US
    Published Date: January 23, 2021
    Which patient-reported outcomes do rheumatology patients find important to track digitally? A real-world longitudinal study in ArthritisPower
    Published Date: February 10, 2021
    Probabilistic linkage of randomized controlled trial data to administrative claims: a case study of patients from baricitinib clinical trials
    Published Date: April 2, 2021
    Comorbidities of alopecia areata: a population-based cohort study
    Published Date: June 1, 2021
    Alopecia areata treatment patterns, healthcare resource utilization, and comorbidities in the US population using insurance claims
    Published Date: July 22, 2021
    Prevalence of renal impairment in a US commercially insured rheumatoid arthritis population: a retrospective analysis
    Published Date: July 28, 2021
    A Systematic Literature Review of Residual Symptoms and Unmet Need in Patients with Rheumatoid Arthritis
    Published Date: July 3, 2020
    The Role of Patients in Alopecia Areata Endpoint Development: Understanding Physical Signs and Symptoms
    Published Date: November, 2020

    Omvoh® (mirikizumab)

    Full Prescribing Information

    No Publication Journals

    Mirikizumab pharmacokinetics and exposure-response in pediatric patients with moderate-to-severe ulcerative colitis
    Published Date: December, 2024
    Effects of Mirikizumab on Histologic Resolution of Crohn's Disease in a Randomized Controlled Phase 2 Trial
    Published Date: September, 2024
    Mirikizumab Sustained Impact on Fatigue in Patients with Moderately to Severely Active Crohn's Disease in the Phase 2 AMAG Study
    Published Date: August, 2024
    Mirikizumab Regulates Genes Involved in Ulcerative Colitis Disease Activity and Anti-TNF Resistance: Results From a Phase 2 Study
    Published Date: July, 2023
    Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn’s Disease
    Published Date: February, 2022

    Efficacy and Safety of Mirikizumab in the Treatment of Moderately to Severely Active Ulcerative Colitis Regardless of Baseline Modified Mayo Score: Results From the Phase 3 LUCENT Trials
    Published Date: January, 2025
    Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials
    Published Date: December, 2024
    Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study
    Published Date: December, 2024
    Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study
    Published Date: December, 2024
    Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results from the LUCENT-3 Open-Label Extension Study
    Published Date: October, 2024
    Resolving Histological Inflammation in Ulcerative Colitis With Mirikizumab in the LUCENT Induction and Maintenance Trial Programmes
    Published Date: September, 2023
    Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis
    Published Date: June, 2023

    No Publication Journals

    Change in Urgency Status Among Ulcerative Colitis Patients: Understanding a Potential Unmet Patient Need from the CorEvitas Inflammatory Bowel Disease Registry
    Published Date: April 5, 2023
    Disease Burden and Patient-Reported Outcomes Among Ulcerative Colitis Patients According to Therapy at Enrollment Into CorEvitas' Inflammatory Bowel Disease Registry
    Published Date: March 8, 2022

    Taltz® (ixekizumab)

    Full Prescribing Information

    No Publication Journals

    No Publication Journals

    No Publication Journals

    Comparison of Real-World Costs, Healthcare Resource Utilization, and Comorbidity-Related Costs Between Ixekizumab and Secukinumab Among Biologic-Experienced Patients with Psoriasis Over 18 Months in the USA.
    Published Date: February 25, 2023
    Changes in musculoskeletal disease activity and patient-reported outcomes in patients with psoriatic arthritis treated with ixekizumab: results from a real-world US cohort.
    Published Date: June 21, 2023
    Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs.
    Published Date: January 31, 2022
    Employment, Work Productivity, and Biologic Treatments in Self-Reported Axial Spondyloarthritis: a Cross-Sectional Study in a Female Predominant Population from the ArthritisPower Registry
    Published Date: February 21, 2022
    Long-Term Treatment Patterns Among Patients With Psoriasis Treated With Ixekizumab or Adalimumab: A Real-World Study.
    Published Date: March 28, 2022
    Healthcare resource utilization and costs among patients with psoriasis treated with ixekizumab or adalimumab over 2 years of follow-up in real-world settings.
    Published Date: June 6, 2022
    Healthcare Costs Among Patients with Psoriasis Treated with Ixekizumab Versus Secukinumab in Real-World Settings Over 24 Months.
    Published Date: September 26, 2022
    Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: The Corrona Psoriasis Registry.
    Published Date: January 25, 2021
    Comparing symptoms, treatment patterns, and quality of life of ankylosing spondylitis and non-radiographic axial spondyloarthritis patients in the USA: findings from a patient and rheumatologist Survey.
    Published Date: February 20, 2021
    Evaluation of changes in skin and joint outcomes and associated treatment changes in PsA: Experience from the  Corrona PsA/SpA Registry
    Published Date: March 1, 2021
    Real-World Claims Analyses of Comorbidity Burden, Treatment Pattern, Healthcare Resource Utilization, and Costs in Pediatric Psoriasis.
    Published Date: June 6, 2021
    Comparison of Two-Year Treatment Adherence, Persistence, Discontinuation, Re-initiation, and Switching Between Psoriasis Patients Treated with Ixekizumab or Secukinumab in Real-World Settings
    Published Date: July 8 2021
    Real-World Treatment Patterns and Healthcare Costs in Patients with Psoriatic Arthritis Treated with Ixekizumab: A Retrospective Study
    Published Date: September 22, 2021
    Clinical and Quality of Life Outcomes among Ixekizumab Treated Psoriasis Patients in a Real-World Setting
    Published Date: October 6, 2021
    Treatment Satisfaction and Decision Making from the Patient Perspective in Axial Spondyloarthritis: Real-World Data from the ArthritisPower Registry
    Published Date: October 10, 2021
    Comparison of Real-world Treatment Patterns among Biologic-experienced Patients with Psoriasis Treated with Ixekizumab or Secukinumab over 18 Months
    Published Date: October 15, 2021
    Disease Response and Patient-Reported Outcome Measures Among Initiators of Ixekizumab
    Published Date: December 2, 2020
    Understanding patient demographic, clinical, and treatment history of patients newly initiating ixekizumab: Findings from the Corrona Psoriasis Registry
    Published Date: December 23, 2021
    Disease characteristics and the burden of joint and skin involvement amongst people with psoriatic arthritis: a population survey
    Published Date: July 22, 2020

    Can't find what you're looking for? Contact us for answers to your medical questions.

    • Copyright
    • Terms of Use
    • Privacy Statement
    • Consumer Health Privacy Notice
    • Accessibility Statement
    • Sitemap
       

      This site is intended for US Healthcare Professionals only.

      4.0.66 5/2025 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2025. All rights reserved.

      Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

      California Consumer Privacy Act (CCPA) Opt-Out Icon Your Privacy Choices
      Cookie Settings
      Facebook X LinkedIn
      Lilly